Herantis Pharma: Approved delisting application regarding the secondary listing on the Nasdaq First North Growth Market Sweden
Herantis Pharma Plc, Company release, 5 December 2022 at 09:00 EET Herantis Pharma will be traded solely on Nasdaq First North Growth Market Finland under the trading code: HRTIS Herantis Pharma Plc ("Herantis") is developing disease modifying therapies for Parkinson’s disease. As announced on December 1, 2022, Herantis applied for delisting of its shares from Nasdaq First North Growth Market Sweden (“Nasdaq FN GM Sweden”). Nasdaq Stockholm AB approved the application December 2, 2022 and decided to delist the shares of Herantis (trading code HRNTS, ISIN code FI4000087861)